Tesamorelin 2 Milligrams (MG)

Phase 2Small molecule

Tesamorelin 2 Milligrams (MG) is one of 3 small molecule programs targeting Peripheral Nerve Injury. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral Nerve InjuryRecruiting

Peripheral Nerve InjuryPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Peripheral Nerve Injury

#DrugCompanyPhaseTrials

Golytely

Xylocaine

1 3

Tesamorelin 2 Milligrams (MG)

JJohns Hopkins University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Peripheral Nerve Injury

NCT03150511

Clinical

Trials by Indication[1]

Peripheral Nerve Injury1 trial

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

Recruiting·JJohns Hopkins University·Phase 2·NCT03150511·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tesamorelin 2 Milligrams (MG). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tesamorelin 2 Milligrams (MG) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tesamorelin 2 Milligrams (MG). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johns Hopkins University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJohns Hopkins University

Tesamorelin 2 Milligrams (MG)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Peripheral Nerve Injury1 trial

References

Drug Info

Quick Facts

Related News